Therapeutic approaches to modulating Notch signaling: Current challenges and future prospects

Dexter, 1914, The analysis of a case of continuous variation in Drosophila by a study of its linkage relations, Am Nat, 48, 712, 10.1086/279446 Ellisen, 1991, TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms, Cell, 66, 649, 10.1016/0092-8674(91)90111-B Weng, 2004, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia, Science, 306, 269, 10.1126/science.1102160 Wang, 2010, Notch signaling proteins: legitimate targets for cancer therapy, Curr Protein Pept Sci, 11, 398, 10.2174/138920310791824039 Tolia, 2009, Structure and function of γ-secretase, Semin Cell Dev Biol, 20, 211, 10.1016/j.semcdb.2008.10.007 Wolfe, 1998, A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity, J Med Chem, 41, 6, 10.1021/jm970621b Li, 2000, Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state, Proc Natl Acad Sci USA, 97, 6138, 10.1073/pnas.110126897 Bihel, 2004, Discovery of a subnanomolar helical D-tridecapeptide inhibitor of γ-secretase, J Med Chem, 47, 3931, 10.1021/jm049788c Seiffert, 2000, Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors, J Biol Chem, 275, 34086, 10.1074/jbc.M005430200 Dovey, 2001, Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain, J Neurochem, 76, 173, 10.1046/j.1471-4159.2001.00012.x May, 2002, Chronic treatment with a functional γ-secretase inhibitor reduces Aβ burden and plaque pathology in PDAPP mice, Neurobiol Aging, 23, S133 Lanz, 2006, Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139, J Pharmacol Exp Ther, 319, 924, 10.1124/jpet.106.110700 Wolfe, 2012, γ-Secretase inhibitors and modulators for Alzheimer's disease, J Neurochem, 120, 89, 10.1111/j.1471-4159.2011.07501.x Golde, 2011, Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift, Neuron, 69, 203, 10.1016/j.neuron.2011.01.002 Karran, 2011, The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics, Nat Rev Drug Discov, 10, 698, 10.1038/nrd3505 Searfoss, 2003, Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor, J Biol Chem, 278, 46107, 10.1074/jbc.M307757200 Wong, 2004, Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation, J Biol Chem, 279, 12876, 10.1074/jbc.M311652200 van Es, 2005, Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells, Nature, 435, 959, 10.1038/nature03659 Malecki, 2006, Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes, Mol Cell Biol, 26, 4642, 10.1128/MCB.01655-05 Sulis, 2008, NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL, Blood, 112, 733, 10.1182/blood-2007-12-130096 Mansour, 2007, Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia, Clin Cancer Res, 13, 6964, 10.1158/1078-0432.CCR-07-1474 Palomero, 2006, CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors, Leukemia, 20, 1279, 10.1038/sj.leu.2404258 O’Neil, 2006, Activating Notch1 mutations in mouse models of T-ALL, Blood, 107, 781, 10.1182/blood-2005-06-2553 Kogoshi, 2007, γ-Secretase inhibitors suppress the growth of leukemia and lymphoma cells, Oncol Rep, 18, 77 De Keersmaecker, 2008, In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia, Haematologica, 93, 533, 10.3324/haematol.11894 Wei, 2010, Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design, Mol Cancer Ther, 9, 1618, 10.1158/1535-7163.MCT-10-0034 Lewis, 2007, Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of Notch signaling, Chem Biol, 14, 209, 10.1016/j.chembiol.2006.12.010 O’Neil, 2007, FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors, J Exp Med, 204, 1813, 10.1084/jem.20070876 Tammam, 2009, Down-regulation of the Notch pathway mediated by a γ-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia, Br J Pharmacol, 158, 1183, 10.1111/j.1476-5381.2009.00389.x Kolb, 2011, Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting Notch signaling, Pediatr Blood Cancer, 10.1002/pbc.22741 Palomero, 2007, Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia, Nat Med, 13, 1203, 10.1038/nm1636 Milano, 2004, Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation, Toxicol Sci, 82, 341, 10.1093/toxsci/kfh254 Deangelo, 2006, A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias, J Clin Oncol, 24, 6585, 10.1200/jco.2006.24.18_suppl.6585 Hubmann, 2002, Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia, Blood, 99, 3742, 10.1182/blood.V99.10.3742 Jundt, 2002, Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma, Blood, 99, 3398, 10.1182/blood.V99.9.3398 Jundt, 2004, Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells, Blood, 103, 3511, 10.1182/blood-2003-07-2254 Nefedova, 2004, Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines, Blood, 103, 3503, 10.1182/blood-2003-07-2340 Morimura, 2000, Cell cycle arrest and apoptosis induced by Notch1 in B cells, J Biol Chem, 275, 36523, 10.1074/jbc.M006415200 Romer, 2003, Notch1 enhances B-cell receptor-induced apoptosis in mature activated B cells without affecting cell cycle progression and surface IgM expression, Cell Death Differ, 10, 833, 10.1038/sj.cdd.4401253 Zweidler-McKay, 2005, Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies, Blood, 106, 3898, 10.1182/blood-2005-01-0355 Houde, 2004, Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines, Blood, 104, 3697, 10.1182/blood-2003-12-4114 Schwarzer, 2008, Notch inhibition blocks multiple myeloma cell-induced osteoclast activation, Leukemia, 22, 2273, 10.1038/leu.2008.138 Tohda, 2006, Establishment of a novel B-cell lymphoma cell line with suppressed growth by γ-secretase inhibitors, Leuk Res, 30, 1385, 10.1016/j.leukres.2006.05.003 Meng, 2011, GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia, Leukemia, 25, 1135, 10.1038/leu.2011.50 Han, 2009, The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition, Breast Cancer Res, 11, R57, 10.1186/bcr2347 Nefedova, 2008, Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy, Blood, 111, 2220, 10.1182/blood-2007-07-102632 Jhappan, 1992, Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands, Genes Dev, 6, 345, 10.1101/gad.6.3.345 Gallahan, 1997, The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4), Oncogene, 14, 1883, 10.1038/sj.onc.1201035 Dievart, 1999, Involvement of Notch1 in the development of mouse mammary tumors, Oncogene, 18, 5973, 10.1038/sj.onc.1202991 Imatani, 2000, Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines, Oncogene, 19, 223, 10.1038/sj.onc.1203295 Kiaris, 2004, Modulation of Notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium, Am J Pathol, 165, 695, 10.1016/S0002-9440(10)63333-0 Weijzen, 2002, Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells, Nat Med, 8, 979, 10.1038/nm754 Reedijk, 2005, High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival, Cancer Res, 65, 8530, 10.1158/0008-5472.CAN-05-1069 Parr, 2004, The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer, Int J Mol Med, 14, 779 Stylianou, 2006, Aberrant activation of Notch signaling in human breast cancer, Cancer Res, 66, 1517, 10.1158/0008-5472.CAN-05-3054 Dontu, 2003, Stem cells in normal breast development and breast cancer, Cell Prolif, 36, 59, 10.1046/j.1365-2184.36.s.1.6.x Zavadil, 2004, Integration of TGF-β/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition, EMBO J, 23, 1155, 10.1038/sj.emboj.7600069 Collins, 2004, Notch in lung development and lung cancer, Semin Cancer Biol, 14, 357, 10.1016/j.semcancer.2004.04.015 Sriuranpong, 2001, Notch signaling induces cell cycle arrest in small cell lung cancer cells, Cancer Res, 61, 3200 Dang, 2000, Chromosome 19 translocation, overexpression of Notch3, and human lung cancer, J Natl Cancer Inst, 92, 1355, 10.1093/jnci/92.16.1355 Chen, 1997, Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression, Proc Natl Acad Sci USA, 94, 5355, 10.1073/pnas.94.10.5355 Dang, 2003, Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice, Oncogene, 22, 1988, 10.1038/sj.onc.1206230 Konishi, 2007, γ-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers, Cancer Res, 67, 8051, 10.1158/0008-5472.CAN-07-1022 Rizzo, 2008, Rational targeting of Notch signaling in cancer, Oncogene, 27, 5124, 10.1038/onc.2008.226 Curry, 2005, γ-Secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells, Oncogene, 24, 6333, 10.1038/sj.onc.1208783 Suwanjunee, 2008, Inhibition of γ-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling, Anticancer Drugs, 19, 477, 10.1097/CAD.0b013e3282fc6cdd Plentz, 2009, Inhibition of γ-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma, Gastroenterology, 136, 1741, 10.1053/j.gastro.2009.01.008 Luistro, 2009, Preclinical profile of a potent γ-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties, Cancer Res, 69, 7672, 10.1158/0008-5472.CAN-09-1843 Fan, 2006, Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors, Cancer Res, 66, 7445, 10.1158/0008-5472.CAN-06-0858 Real, 2009, γ-Secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia, Nat Med, 15, 50, 10.1038/nm.1900 Pandya, 2011, Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence, Br J Cancer, 105, 796, 10.1038/bjc.2011.321 Osipo, 2008, ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor, Oncogene, 27, 5019, 10.1038/onc.2008.149 Kelly, 2007, Notch-induced T cell development requires phosphoinositide-dependent kinase 1, EMBO J, 26, 3441, 10.1038/sj.emboj.7601761 Meurette, 2009, Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells, Cancer Res, 69, 5015, 10.1158/0008-5472.CAN-08-3478 Efferson, 2010, Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model, Cancer Res, 70, 2476, 10.1158/0008-5472.CAN-09-3114 Meng, 2009, γ-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity, Cancer Res, 69, 573, 10.1158/0008-5472.CAN-08-2088 Li, 2010, Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect, Mol Cancer Ther, 9, 3200, 10.1158/1535-7163.MCT-10-0372 Chen, 2011, γ-Secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma, Cell Oncol (Dordr), 34, 545, 10.1007/s13402-011-0060-6 Vo, 2011, Targeting Notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation, Mol Cancer, 10, 138, 10.1186/1476-4598-10-138 Li, 2008, Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3, J Biol Chem, 283, 8046, 10.1074/jbc.M800170200 Wu, 2010, Therapeutic antibody targeting of individual Notch receptors, Nature, 464, 1052, 10.1038/nature08878 Aste-Amézaga, 2010, Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors, PLoS One, 5, e9094, 10.1371/journal.pone.0009094 Elyaman, 2007, Jagged1 and Delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis, J Immunol, 179, 5990, 10.4049/jimmunol.179.9.5990 Hoey, 2009, DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency, Cell Stem Cell, 5, 168, 10.1016/j.stem.2009.05.019 Fischer, 2011, Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations, Cancer Res, 71, 1520, 10.1158/0008-5472.CAN-10-2817 Moellering, 2009, Direct inhibition of the NOTCH transcription factor complex, Nature, 462, 182, 10.1038/nature08543 Hayashi, 2011, Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin, Oncogene Funahashi, 2008, A Notch1 ectodomain construct inhibits endothelial Notch signaling, tumor growth, and angiogenesis, Cancer Res, 68, 4727, 10.1158/0008-5472.CAN-07-6499 Moss, 2008, ADAM10 as a target for anti-cancer therapy, Curr Pharm Biotechnol, 9, 2, 10.2174/138920108783497613 Weng, 2003, Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of Notch signaling, Mol Cell Biol, 23, 655, 10.1128/MCB.23.2.655-664.2003 Maillard, 2004, Mastermind critically regulates Notch-mediated lymphoid cell fate decisions, Blood, 104, 1696, 10.1182/blood-2004-02-0514 Kavian, 2010, Targeting ADAM-17/Notch signaling abrogates the development of systemic sclerosis in a murine model, Arthritis Rheum, 62, 3477, 10.1002/art.27626 Jacobs, 1916, Some biological and practical aspects of growth, Univ Bull Univ Penn, 17, 131 Lanz, 2010, Pharmacodynamics and pharmacokinetics of the γ-secretase inhibitor PF-3084014, J Pharmacol Exp Ther, 334, 269, 10.1124/jpet.110.167379 Fouladi, 2011, Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study, J Clin Oncol, 29, 3529, 10.1200/JCO.2011.35.7806